Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort

Chen, Ru; Wang, Jing; Tang, Shaowen; Zhang, Yuan; Lv, Xiaozhen; Wu, Shanshan; Xia, Yuqing; Deng, Peiyuan; Ma, Yu; Tu, Dehua; Chen, Dafang; Zhan, Siyan

doi:10.1016/j.tube.2014.11.004

Cited by 23 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a continuously increasing number of identified sequences of polymorphisms related to the occurrence of antituberculosis drug-induced hepatotoxicity (ATDH): for example, genetic variants within N-acetyltransferase 2 (NAT2), nuclear receptor subfamily 1 group I member 2 (PXR), and solute carrier organic anion transporter family member 1B1 (SLCO1B1) genes. [13][14][15] Several published literatures have shown that lncRNAs are significantly associated with the drug effects and resistance in various malignant diseases. 16,17 For example, in the breast cancer cell experiment, researchers found that downregulation of lncRNA ROR inhibited the resistance to Tamoxifen.…”

Section: Found Aberrant Expressionmentioning

confidence: 99%

“…For antituberculosis drugs (ATDs), hepatotoxicity is known as the most serious and prevalent adverse drug reaction. There are a continuously increasing number of identified sequences of polymorphisms related to the occurrence of antituberculosis drug‐induced hepatotoxicity (ATDH): for example, genetic variants within N‐acetyltransferase 2 ( NAT2 ), nuclear receptor subfamily 1 group I member 2 ( PXR ), and solute carrier organic anion transporter family member 1B1 ( SLCO1B1 ) genes . Several published literatures have shown that lncRNAs are significantly associated with the drug effects and resistance in various malignant diseases .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic polymorphisms of long noncoding RNA RP11‐37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China

Song

Liu

Zhao

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundLittle knowledge about the biological functions of RP11‐37B2.1, a newly defined long noncoding RNA (lncRNA) molecule, is currently available. Previous studies have shown rs160441, located in the RP11‐37B2.1 gene, is significantly associated with tuberculosis (TB) in a Ghanaian and the Gambian populations.MethodsWe investigated the influence of single‐nucleotide polymorphisms (SNPs) within lncRNA RP11‐37B2.1 on the risk of TB and the possible correlation with adverse drug reactions (ADRs) from TB treatment in a Western Chinese population. Four SNPs within lncRNA RP11‐37B2.1 were genotyped in 554 TB cases and 561 healthy subjects using the improved multiplex ligation detection reaction method, and the patients were followed up monthly to monitor the development of ADRs.ResultsNo significant association between the SNPs of lncRNA RP11‐37B2.1 and TB susceptibility was observed (all P > 0.05). Surprisingly, significant association was observed between two SNPs (rs218916 and rs160441) and thrombocytopenia development during anti‐TB therapy under the dominant model (P = 0.003 and 0.014, respectively).ConclusionsOur findings firstly exhibit that rs218916 and rs160441 within lncRNA RP11‐37B2.1 significantly associate with the occurrence of thrombocytopenia and suggest RP11‐37B2.1 genetic variants are potential biosignatures for thrombocytopenia during anti‐TB treatment.

show abstract

Section: Found Aberrant Expressionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms of long noncoding RNA RP11‐37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China

Song

Liu

Zhao

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Twenty-two articles employed a case–control design (7, 24, 25, 27, 29–38, 40, 44, 45, 48–52), and 13 articles employed a prospective cohort design (22, 23, 26, 28, 41–43, 46, 47, 53–56). Only one (29) of the 22 articles describing case-control studies reported that the two groups were genotyped in mixed batches.…”

Section: Resultsmentioning

confidence: 99%

“…Only eight articles mentioned genotype quality control procedures (7, 25, 26, 29, 30, 48, 51, 52), and therefore genotyping results from the remaining 27 articles should be interpreted with caution due to the risk of bias from incorrect genotype allocation. Only six articles (24, 32, 35, 41, 43, 47) compared genotype frequencies of all investigated SNPs with those previously published for the same population, a simple way of highlighting problems with genotyping.…”

Section: Resultsmentioning

confidence: 99%

Association of variants within the GST and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis

Richardson

Kirkham

Dwan

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Individuals receiving treatment with anti-tuberculosis (TB) drugs may experience serious side-effects, such as anti-TB drug-induced hepatotoxicity (ATDH). Genetic variants, such as polymorphisms of the GST gene and other genes, may increase the risk of experiencing such toxicity events. This systematic review and meta-analysis provides a comprehensive evaluation of the evidence base for associations between variants of the GST gene and other genes and toxicity outcomes related to anti-TB drugs. Methods We searched for relevant studies in MEDLINE, PubMed, EMBASE, BIOSIS and Web of Science. We pooled effect estimates for each genotype on each outcome, and stratified all analyses by country. We qualitatively assessed the methodological quality of the included studies. Results We included data from 28 distinct cohorts of patients in the review. The methodological quality of included studies was variable, with several important areas of concern. For GSTM1, patients with the homozygous null genotype were significantly more likely to experience hepatotoxicity than patients with heterozygous or homozygous present genotype (odds ratio [OR]=1.44, 95% confidence interval [CI] 1.15, 1.82). Moderate heterogeneity was observed in this analysis (I2=51.2%). No significant difference was observed for the GSTT1 null polymorphism. For the rs3814057 polymorphism of the PXR gene, both heterozygous genotype and homozygous mutant-type significantly increased hepatotoxicity risk compared with homozygous wild-type (heterozygous versus homozygous wild-type: OR=1.98, 95% CI 1.06, 3.69; I2=0%; homozygous mutant-type versus homozygous wild-type: OR=2.18, 95% CI 1.07, 4.44; I2=0%). Conclusions We found that it is challenging to perform robust synthesis of the evidence base for associations between GST and other genetic variants and toxicity related to anti-TB drugs. We identified significant associations between the GSTM1 null and PXR rs3814057 polymorphisms and ATDH. To the best of our knowledge, no meta-analyses on genetic variants other than variants of the NAT2, CYP2E1, GSTM1 and GSTT1 genes have been published. Our results therefore add to the existing understanding of the association between genetic variants and hepatotoxicity.

show abstract

“…For instance, association of polymorphisms in Nacetyltransferase 2 (NAT2) (Cho et al, 2007;Du et al, 2013;Huang et al, 2002;Ohno et al, 2000;Possuelo et al, 2008;Yimer et al, 2011), cytochrome P450 family-2 subfamily-E member-1 (CYP2E1) Huang et al, 2003;Vuilleumier et al, 2006), glutathione S-transferases M1 (GSTM1) (Huang et al, 2007;Li et al, 2013;Roy et al, 2001), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) (Chang et al, 2012), ATP-binding cassette subfamily-B member-1 (ABCB1) (Yimer et al, 2011), solute carrier organic anion transporter family member-1B1 (SLCO1B1) (Chen et al, 2015a;Li et al, 2012), mitochondrial superoxide dismutase (SOD2) (Huang et al, 2007), and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway (Nanashima et al, 2012) genes with antituberculosis DIH has been reported previously.…”

Section: Candidate Gene Association Studiesmentioning

confidence: 99%

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back–Looking Forward to Next-Generation Innovation

Petros

Makonnen

Aklillu

2017

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Idiosyncratic drug-induced hepatotoxicity is a formidable challenge for rational drug discovery and development, as well as the science of personalized medicine. There is evidence that hereditary factors, in part, contribute to drug toxicity. This expert analysis and review offer the insights gained, and the challenges ahead, for genome-wide association studies (GWASs) of idiosyncratic drug-induced hepatotoxicity. Published articles on genome-wide and subsequent replication studies were systematically searched in the PubMed electronic database. We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity. Additionally, polymorphisms in ST6 b-galactosamide a-2, 6-sialyltranferase-1 (ST6GAL1), which plays a role in systemic inflammatory response, and variants in intron of family with sequence similarity-65 member-B (FAM65B) that play roles in liver inflammation displayed association with flucloxacillin and antituberculosis drug-induced hepatotoxicity, respectively. Taken together, these GWAS findings offer molecular leads on the central role that the immune system plays in idiosyncratic drug-induced hepatotoxicity. We conclude the expert review with a brief discussion of the salient challenges ahead. These include, for example, the need for discursive discovery paradigms that incorporate alternating GWASs and candidate gene studies, as well as the study of the environtome, the entire complement of environmental factors, including science and innovation policies that enact on global society and the human host, and by extension, on susceptibility for idiosyncratic drug-induced hepatotoxicity.

show abstract

Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort

Cited by 23 publications

References 34 publications

Genetic polymorphisms of long noncoding RNA RP11‐37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China

Genetic polymorphisms of long noncoding RNA RP11‐37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China

Association of variants within the GST and other genes with anti-tubercular agents related toxicity: a systematic review and meta-analysis

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back–Looking Forward to Next-Generation Innovation

Contact Info

Product

Resources

About